Upstream Bio's Phase 2 trial for verekitug shows strong results in cutting asthma attacks, but only the every-12-week dose matches rivals. Stock dips as experts weigh in on future plans and competition.
FDA refuses to review Moderna's innovative mRNA flu vaccine over clinical trial design concerns, sending shares down 7%. Company disputes decision citing prior agency approval.
GSK purchases RAPT Therapeutics for $2.2B, gaining ozureprubart - a promising food allergy treatment requiring injections every 12 weeks instead of every 2 weeks.
GSK and Ionis announce breakthrough results for bepirovirsen, a potential first-in-class treatment offering functional cure for chronic hepatitis B in just six months.
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
Spero Therapeutics announces $25 million milestone payment following GSK's FDA resubmission for tebipenem HBr antibiotic treatment for urinary tract infections.
